Zugriffszahlen seit März 2016. Zugriffszahlen aus dem Vorgängersystem werden nicht mitberücksichtigt.

Total Visits

Views
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy25

Total Visits Per Month

May 2021June 2021July 2021August 2021September 2021October 2021November 2021
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy3163002

Top country views

Views

Top cities views

Views